Keyword: UC San Francisco
The biotech aims to differentiate itself with technology that enables the insertion of large DNA sequences without the use of viral vectors.
The week’s biotech news included a form of CRISPR that can edit 25 genes at once and a drug that helps blood cells recover from cancer treatment.
Bioengineers at UCSF and the University of Washington have designed a protein that can be switched on and off inside cells to modulate healing.
Two research groups have uncovered clues to immuno-oncology drug resistance, offering insight that could lead to new treatment strategies.
A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.
The week’s biotech news included an eFFECTOR drug that slows liver cancer in mice and insight into age-related muscle decline.
UCSF researchers have modified CRISPR gene editing to increase the activity of genes that create the feeling of being full.
Combining EGFR inhibitors with drugs targeting Aurora kinase A killed cancer cells permanently, a University of California, San Francisco, team found.
Livongo and the University of California, San Francisco, launched a randomized, controlled trial that will recruit 300 adults with Type 2 diabetes.
A UCSF spinoff is working with GlaxoSmithKline to develop a drug to target a common mutation in glioblastoma.